GlassScriptPhysician profile
C Kent Titus
NPI 1962481382
$510.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $42.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.53 | 2019 | |
| Novo Nordisk INC | $81.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.29 | 2019-2020 | |
| Pfizer INC. | $38.90 | 2019 | |
| Lilly USA, LLC | $37.71 | 2019 | |
| Bausch Health US, LLC | $33.81 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $33.77 | 2019 | |
| Sanofi Pasteur INC. | $31.04 | 2019 | |
| Astellas Pharma US INC | $26.87 | 2019 | |
| Edwards Lifesciences Corporation | $21.05 | 2019 | |
| Amarin Pharma, INC. | $15.30 | 2019 | |
| Shire North American Group INC | $12.59 | 2019 | |
| Genentech USA, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Titus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.